Biblio Discovery — Demo Discovery Service

5 results for "T. Quaranta"

Showing 1–5 · 3.09 seconds · RSS

  1. Journal Article

    P115 | CUTANEOUS INVOLVEMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD OUTCOMES WITH VENETOCLAX-OBINUTUZUMAB AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS.

    I. Innocenti; A. Tomasso *; L. Stirparo * et al.

    Haematologica, Vol. 110 No. s1 · 2025 · English · DOAJ Scopus

    Introduction: Cutaneous manifestations are rare in patients with chronic lymphocytic leukaemia (CLL) and may result from either direct leukemic infiltration or the general predisposition of CLL patients to secondary conditions. Leukaemia cutis (LC), caused by skin infiltration of leukemic cells, is…

  2. Journal Article

    P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE

    A. Tomasso; I. Innocenti *; L. Stirparo * et al.

    Haematologica, Vol. 110 No. s1 · 2025 · English · DOAJ Scopus

    Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal…

  3. Journal Article

    P106 | ONCOGERIATRIC ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OVER 65 YEARS IN TARGET ERA. A MONOCENTRIC PILOT STUDY AT FONDAZIONE POLICLINICO A. GEMELLI, ROME

    I. Innocenti; L. Stirparo; A. Tomasso et al.

    Haematologica, Vol. 110 No. s1 · 2025 · English · DOAJ Scopus

    Introduction: Chronic lymphocytic leukemia (CLL) primarily affects elderly adults. While targeted agents such as BTKi and BCL-2 inhibitors have improved outcomes, their use in elderly patients raises concerns regarding tolerance and toxicity, and there is still no established method for defining…

  4. Journal Article

    P120 | CHRONIC LYMPHOCYTIC LEUKEMIA AND RENAL CELL CARCINOMA: A CASE SERIES OF TWELVE PATIENTS

    T. Quaranta; F. Guglielmi; A. Tomasso et al.

    Haematologica, Vol. 110 No. s1 · 2025 · English · DOAJ Scopus

    Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a median age at diagnosis of 72 years. CLL patients (pts) have an increased risk of second malignancies due to multiple synergistic factors: genetic, environmental, treatment-induced and immunomodulatory…

  5. Journal Article

    DP046 | ABSENCE OF LYMPHOCYTOSIS INCREASE AFTER STARTING TREATMENT WITH CBTKI IS UNUSUAL AND ASSOCIATED TO SPECIFIC BIOLOGICAL MARKERS

    A. Mosca; I. Innocenti; A. Tomasso et al.

    Haematologica, Vol. 110 No. s1 · 2025 · English · DOAJ Scopus

    Background: Bruton tyrosine kinase inhibitors (BTKi) are a class of drugs that have revolutionized Chronic Lymphocytic Leukemia (CLL) therapy. They inhibit Bruton tyrosine kinase (BTK), an enzyme able to trigger a lot of metabolic ways involved in B lymphocytes surviving, proliferation and…